New digital health player HealthHero launches with Fernarzt buyThere’s a new kid on the block in digital health – called HealthHero – with aspirations to become Share XNew digital health player HealthHero launches with Fernarzt buyhttps://pharmaphorum.com/news/new-digital-health-player-healthhero-launches-with-fernarzt-buy/
Roche’s NTRK tumour-agnostic therapy Rozlytrek approved in EuropeRoche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK Share XRoche’s NTRK tumour-agnostic therapy Rozlytrek approved in Europehttps://pharmaphorum.com/news/roches-tumour-agnostic-therapy-approved-in-europe/
Regeneron pairs with BioNTech on melanoma immunotherapyRegeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech Share XRegeneron pairs with BioNTech on melanoma immunotherapyhttps://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/
US pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccineThe US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 Share XUS pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccinehttps://pharmaphorum.com/news/us-pays-sanofi-gsk-100-million-doses-covid-19-vaccine/
NICE backs kidney cancer combination from Merck KGaA and PfizerNICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first Share XNICE backs kidney cancer combination from Merck KGaA and Pfizerhttps://pharmaphorum.com/news/nice-backs-kidney-cancer-combination-from-merck-kgaa-and-pfizer/
The Planning Shop names Rebecca Rehder as global presidentBrand consultancy The Planning Shop has appointed Rebecca Rehder as global president, leading the organisation across the UK Share XThe Planning Shop names Rebecca Rehder as global presidenthttps://pharmaphorum.com/news/planning-shop-rebecca-rehder-global-president/
Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisitionGilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – Share XGilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisitionhttps://pharmaphorum.com/news/gilead-blames-3-3-billio/
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surgeRoche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – Share XRoche’s Tecentriq claims melanoma OK, but don’t expect a sales surgehttps://pharmaphorum.com/news/roches-tecentriq-claims-melanoma-ok-but-dont-expect-a-sales-surge/
NHSX launches procurement tool as pager phase-out begins in earnestNHSX, the government agency tasked with digitally transforming the UK’s health service, has launched a service to help Share XNHSX launches procurement tool as pager phase-out begins in earnesthttps://pharmaphorum.com/news/nhsx-launches-procurement-tool-as-pager-phase-out-begins-in-earnest/
Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failureThe FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Share XStudy puts Jardiance in hot pursuit of AZ’s Farxiga in heart failurehttps://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/
BMS ‘bet’ with Celgene shareholders in balance after CAR-T refileBristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a Share XBMS ‘bet’ with Celgene shareholders in balance after CAR-T refilehttps://pharmaphorum.com/news/bms-2/
AstraZeneca beats expectations in Q2, while GSK struggles during pandemicAstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been Share XAstraZeneca beats expectations in Q2, while GSK struggles during pandemichttps://pharmaphorum.com/news/az-beats-analysts-expectations-in-q2-while-gsk-struggles-during-pandemic/
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mRoche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a Share XRoche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mhttps://pharmaphorum.com/news/roche-doubles-down-on-tau-for-alzheimers-licensing-ucb-drug-for-120m/
Trump reiterates hydroxychloroquine defense after son is banned from TwitterDonald Trump has launched another defence of hydroxychloroquine as a treatment for COVID-19 which goes against prevailing medical Share XTrump reiterates hydroxychloroquine defense after son is banned from Twitterhttps://pharmaphorum.com/news/trump-reiterates-hydroxychloroquine-defense-after-son-is-banned-from-twitter/
Indigo raises 38 million euros for ‘invisible’ diabetes glucose sensorMedical device company Indigo Diabetes has raised 38 million euros to develop an “invisible” sensor for people with Share XIndigo raises 38 million euros for ‘invisible’ diabetes glucose sensorhttps://pharmaphorum.com/news/indigo-raises-38-million-euros-for-invisible-diabetes-glucose-sensor/
Pfizer ups guidance as it prepares to sell off generics divisionPfizer has cautiously upped its guidance despite second quarter figures showing a slip in sales and profitability compared Share XPfizer ups guidance as it prepares to sell off generics divisionhttps://pharmaphorum.com/news/pfizer-ups-guidance-as-it-prepares-to-sell-off-generics-division/
Setback in COVID-19 effort as Roche’s Actemra fails in key trialRoche’s anti-inflammatory drug Actemra has failed in a phase 3 clinical trial that was testing to see if Share XSetback in COVID-19 effort as Roche’s Actemra fails in key trialhttps://pharmaphorum.com/news/setback-in-covid-19-effort-as-roches-actemra-fails-in-key-trial/
UK places order for 60m doses of Sanofi/GSK’s COVID-19 vaccineThe UK government has signed its fourth coronavirus vaccine deal, snapping up 60 million doses of an experimental Share XUK places order for 60m doses of Sanofi/GSK’s COVID-19 vaccinehttps://pharmaphorum.com/news/uk-places-order-for-60m-doses-of-sanofi-gsks-covid-19-vaccine/
New speaker session with Kiniksa Pharmaceuticals at Pre-filled Syringes East Coast 2020 Share XNew speaker session with Kiniksa Pharmaceuticals at Pre-filled Syringes East Coast 2020https://pharmaphorum.com/partner-content/new-speaker-session-with-kiniksa-pharmaceuticals-at-pre-filled-syringes-east-coast-2020/
Managing and Tracking Cross-functional KOL Collaborations Share XManaging and Tracking Cross-functional KOL Collaborationshttps://pharmaphorum.com/partner-content/managing-and-tracking-cross-functional-kol-collaborations/
Understanding COVID-19 and varying responses across the globe Share XUnderstanding COVID-19 and varying responses across the globehttps://pharmaphorum.com/partner-content/understanding-covid-19-and-varying-responses-across-the-globe/
J+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTER Share XJ+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTERhttps://pharmaphorum.com/partner-content/jd-forecasting-makes-the-pharma-forecasting-experience-even-better/
Prescient Announces Recent Appointments to the Senior Advisory Team Share XPrescient Announces Recent Appointments to the Senior Advisory Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-the-senior-advisory-team/
Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team Share XPrescient Intelligence & Insight Announces Recent Appointments to the Senior Teamhttps://pharmaphorum.com/partner-content/prescient-intelligence-insight-announces-recent-appointments-to-the-senior-team-2/
